ClinicalTrials.gg
Active, not recruitingNCT07135648Updated Aug 22, 2025

Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current Smokers

An interventional study of VM16 and VM32 in Nicotine, sponsored by Philip Morris Products S.A.. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

A single-center, randomized, controlled, partially blinded, crossover study to evaluate the pharmacokinetics and pharmacodynamics of nicotine following use of two variants of VM 1.0, VM16 and VM32, a nicotine-containing aerosol generator compared to cigarettes in adult current smokers. The participants will be blinded to the variants of VM 1.0 and to the randomized product use sequences. The study will be conducted with 3 periods and 3 sequences.

02

Conditions studied

  • Nicotine
03

In context

Lead sponsor

Philip Morris Products S.A. is the lead sponsor of 49 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has signed the ICF and is able to understand the information provided in the ICF.
  • Male or female participant between 21 and 65 years inclusive.
  • Participant has smoked commercially available or roll-your own cigarettes (no brand restrictions) for at least the last 12 months prior to the Screening visit.
  • Participant has smoked at least 10 commercially available cigarettes per day in the past 30 days prior to the Screening visit and Admission.
  • Nicotine exposure status will be verified by urinary cotinine test (cotinine ≥ 200 ng/mL).
  • Participant has a >18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
  • Participant is available for the entire study period and willing to comply with study procedures, including product use assignments and periods of abstinence from any nicotine/tobacco containing products and willing to adhere to a standardized diet.

Exclusion criteria

Exclusion Criteria:

  • Participant has reasons other than medical (e.g., psychological, social reason) not to be part of the study, as determined by the Principal Investigator or designee.
  • Participant is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners).
  • Participant has a health condition which requires medication or any other finding e.g., safety labs, pulmonary function test, vital signs, physical examination, and medical history, as determined by the Principal Investigator or designee.
  • Participant experiences difficulty with venipuncture and/or poor venous access.
  • Participant has medical conditions which require, or will require during the study, a medical intervention (e.g., start of treatment, surgery, hospitalization).
  • Presence of fever (body temperature >37.5°C) e.g., a fever associated with a symptomatic viral or bacterial infection.
  • Participant has a level \< 11.0 g/dL for females and \< 12.0 g/dL for males at the Screening visit.
  • Participant uses medication that aids in smoking cessation.
  • Participant uses Tetrahydrocannabinol (THC)-containing products.
  • Participant previously attempted to quit using tobacco- or nicotine-containing products within 28 days prior to Admission.
  • Participant has donated plasma within seven days prior to screening or has donated or lost 450 mL or more of whole blood within 8 weeks prior to Screening for males, and in the 12 weeks prior to the Screening visit for females.
  • Participant has a positive serology test for 1/2, or C.
  • Participant has a medical history of alcohol abuse within one year prior to Screening or regular use of alcohol within six months prior to the Screening visit that exceeds 10 units for women or 15 units for men of alcohol per week.
  • Participant has a positive urine drug test.
  • Participant has a positive alcohol breath test.
  • Participant or one of their family members is a current or former employee of the tobacco industry.
  • Participant or one of their family members is an employee of the site or of any other parties involved in the study.
  • Participant has participated in another clinical study within 30 days prior to the Screening visit or concomitantly participates in any other investigational study.
  • Participant has been previously screened or enrolled in this study (except alternates)
  • For female participants only: participant has a positive urine pregnancy test at the Screening visit or at Admission or is a breastfeeding.
  • For females of only: participant does not agree to use an acceptable method of effective .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Product Sequence 1

    On Day 1 to Day 3, after at least 10 hours of abstinence from any nicotine/tobacco containing products and after at least 10 hours of fasting, participants will use one of the three investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: Cigarette; VM32; VM16 / VM16; Cigarette; VM32 / VM32; VM16; Cigarette

    Other: VM16 · Other: VM32 · Other: Cigarette (CC)

  • Active comparator
    Product Sequence 2

    On Day 1 to Day 3, after at least 10 hours of abstinence from any nicotine/tobacco containing products and after at least 10 hours of fasting, participants will use one of the three investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: Cigarette; VM32; VM16 / VM16; Cigarette; VM32 / VM32; VM16; Cigarette

    Other: VM16 · Other: VM32 · Other: Cigarette (CC)

  • Active comparator
    Product Sequence 3

    On Day 1 to Day 3, after at least 10 hours of abstinence from any nicotine/tobacco containing products and after at least 10 hours of fasting, participants will use one of the three investigational products according to randomized product use sequence and as instructed by the investigational site personnel. The list of possible sequences are: Cigarette; VM32; VM16 / VM16; Cigarette; VM32 / VM32; VM16; Cigarette

    Other: VM16 · Other: VM32 · Other: Cigarette (CC)

Interventions

  • OtherVM16

    VM16 contains a liquid with a nicotine concentration of 1.6%

  • OtherVM32

    VM32 contains a liquid with a nicotine concentration of 3.2%

  • OtherCigarette (CC)

    Subjects will provide their own usual brand of commercially available cigarettes

06

What researchers measure

Primary outcomes

  1. Nicotine concentration

    To measure the observed plasma nicotine concentration \[C -5min\] and \[C 12hours\], to describe the plasma concentration-time profile of nicotine and derived pharmacokinetic (PK) parameters from VM16 and VM32 use with a fixed puffing regimen and single cigarette smoking.

    Time frame: From 5 minutes prior to product use to 12 hours after product use

  2. Maximum nicotine concentration

    To measure the maximum observed plasma nicotine concentration \[Cmax\], to describe the plasma concentration-time profile of nicotine and derived pharmacokinetic (PK) parameters from VM16 and VM32 use with a fixed puffing regimen and single cigarette smoking.

    Time frame: From 5 minutes prior to product use to 12 hours after product use

  3. Area under the observed plasma nicotine concentration-time curve (AUC)

    To measure the area under the observed plasma nicotine concentration-time curve (AUC) from the start the first puff (T0) to the timepoint of last quantifiable concentration \[AUC 0-last\] and extrapolated to infinity \[AUC 0-infinity\]

    Time frame: From 5 minutes prior to product use to 12 hours after product use

  4. Time to the observed maximum concentration [Tmax]

    To measure the time to the observed maximum concentration \[Tmax\], to describe the plasma concentration-time profile of nicotine and derived pharmacokinetic (PK) parameters from VM16 and VM32 use with a fixed puffing regimen and single cigarette smoking.

    Time frame: From 5 minutes prior to product use to 12 hours after product use

  5. Elimination rate constant [kel]

    To measure the elimination rate constant \[kel\]\], to describe the plasma concentration-time profile of nicotine and derived pharmacokinetic (PK) parameters from VM16 and VM32 use with a fixed puffing regimen and single cigarette smoking.

    Time frame: From 5 minutes prior to product use to 12 hours after product use

  6. Half-life of nicotine [t1/2]

    To measure half-life of nicotine \[t1/2\], to describe the plasma concentration-time profile of nicotine and derived pharmacokinetic (PK) parameters from VM16 and VM32 use with a fixed puffing regimen and single cigarette smoking.

    Time frame: From 5 minutes prior to product use to 12 hours after product use

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Jul 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartActual
Jul 17, 2025
Primary completionActual
Jul 28, 2025
CompletionEst.
Oct 6, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07135648
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Jul 17, 2025
Primary completion
Jul 28, 2025
Completion
Oct 6, 2025 (estimated)
Last update
Aug 22, 2025

Study contacts

Xavier Jaumont, MD
study chair · Philip Morris Products S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion